Abstract | PURPOSE: SUMMARY: CONCLUSION:
Lomitapide is an oral MTP inhibitor approved for the treatment of HoFH. This agent appears to be a realistic option for patients with HoFH who are unable to attain their LDL-C goal or cannot tolerate statin therapy.
|
Authors | Kyle A Davis, Marta A Miyares |
Journal | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
(Am J Health Syst Pharm)
Vol. 71
Issue 12
Pg. 1001-8
(Jun 15 2014)
ISSN: 1535-2900 [Electronic] England |
PMID | 24865757
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2014 by the American Society of Health-System Pharmacists, Inc. All rights reserved. |
Chemical References |
- Anticholesteremic Agents
- BMS201038
- Benzimidazoles
- Carrier Proteins
- microsomal triglyceride transfer protein
|
Topics |
- Administration, Oral
- Anticholesteremic Agents
(adverse effects, pharmacology, therapeutic use)
- Benzimidazoles
(adverse effects, pharmacology, therapeutic use)
- Carrier Proteins
(antagonists & inhibitors)
- Drug Interactions
- Homozygote
- Humans
- Hyperlipoproteinemia Type II
(drug therapy, physiopathology)
|